Zai Lab Announced That The Center For Drug Evaluation Of China's National Medical Products Administration Has Granted Priority Review To Repotrectinib For Adult Patients With Locally Advanced Or Metastatic ROS1-Positive Non-small-cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Zai Lab announced that China's National Medical Products Administration has granted priority review to Repotrectinib for adult patients with locally advanced or metastatic ROS1-positive non-small-cell lung cancer.
May 18, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zai Lab's Repotrectinib receives priority review from China's National Medical Products Administration for advanced ROS1-positive non-small-cell lung cancer.
The priority review granted to Zai Lab's Repotrectinib by China's National Medical Products Administration is a positive development for the company. This accelerates the approval process and potentially leads to faster market entry, which could result in increased revenues and a positive impact on Zai Lab's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100